Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the
Por um escritor misterioso
Descrição
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma
Metastatic Melanoma Therapies OPDIVO® (nivolumab) + YERVOY® (ipilimumab)
Advances in targeted therapy and immunotherapy for melanoma (Review)
Nivolumab in Combination With Ipilimumab in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma - The ASCO Post
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations - ScienceDirect
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
A new era of proactive melanoma therapy: hit hard, hit early - Haas - 2018 - British Journal of Dermatology - Wiley Online Library
Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer
de
por adulto (o preço varia de acordo com o tamanho do grupo)
